XENON PHARMACEUTICALS INC. Financing Cash Flow
XENON PHARMACEUTICALS INC. (XENE) reported Financing Cash Flow of $843.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $26.00K, a 60.00% decline year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $843.01M, a 73141.79% increase year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $113.54M, a 836.00% increase year-over-year.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.36M.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2025 was $117.11M, a 865.48% increase from fiscal 2024.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2024 was $12.13M, a 96.57% decline from fiscal 2023.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2023 was $353.52M, a 26.95% increase from fiscal 2022.
- XENON PHARMACEUTICALS INC. net cash provided by (used in) financing activities for fiscal 2022 was $278.47M, a 37.78% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $843.04M 10-Q · filed 2026-08-06 | $956.58M derived: sum of 3 quarters · filed 2026-08-06 | $958.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $843.01M 10-Q · filed 2026-05-07 | $956.55M derived: sum of 2 quarters · filed 2026-05-07 | $958.91M derived: sum of 3 quarters · filed 2026-05-07 | $958.98M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $113.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $115.90M derived: sum of 2 quarters · filed 2026-02-26 | $115.96M derived: sum of 3 quarters · filed 2026-08-06 | $117.11M 10-K · filed 2026-02-26 |
| 2025-09-30 | $2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $2.42M derived: sum of 2 quarters · filed 2026-08-06 | $3.58M 10-Q · filed 2025-11-03 | $15.71M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.22M 10-Q · filed 2026-08-06 | $13.35M derived: sum of 3 quarters · filed 2026-08-06 | $13.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.15M 10-Q · filed 2026-05-07 | $13.28M derived: sum of 2 quarters · filed 2026-05-07 | $13.28M derived: sum of 3 quarters · filed 2026-05-07 | $13.28M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $12.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $12.13M derived: sum of 2 quarters · filed 2026-02-26 | $12.13M derived: sum of 3 quarters · filed 2026-02-26 | $12.13M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-03 | $0.00 10-Q · filed 2025-11-03 | $324.01M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | $324.01M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $324.01M derived: sum of 2 quarters · filed 2026-02-26 | ||
| 2023-12-31 | $324.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $353.52M 10-K · filed 2026-02-26 | ||
| 2023-09-30 | $29.51M 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $705.00K derived: sum of 2 quarters · filed 2025-02-27 | $270.60M derived: sum of 3 quarters · filed 2025-02-27 | $278.47M 10-K · filed 2025-02-27 |
| 2022-09-30 | $699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $270.59M derived: sum of 2 quarters · filed 2023-11-08 | $278.46M 10-Q · filed 2023-11-08 | $602.42M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $269.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $277.77M 10-Q · filed 2023-08-09 | $601.72M derived: sum of 3 quarters · filed 2024-02-29 | $606.48M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $7.88M 10-Q · filed 2023-05-09 | $331.83M derived: sum of 2 quarters · filed 2024-02-29 | $336.59M derived: sum of 3 quarters · filed 2024-02-29 | $336.70M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $323.95M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $328.71M derived: sum of 2 quarters · filed 2024-02-29 | $328.82M derived: sum of 3 quarters · filed 2024-02-29 | $447.54M 10-K · filed 2024-02-29 |
| 2021-09-30 | $4.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $4.87M derived: sum of 2 quarters · filed 2022-11-08 | $123.59M 10-Q · filed 2022-11-08 | $123.64M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $111.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $118.83M 10-Q · filed 2022-08-09 | $118.88M derived: sum of 3 quarters · filed 2023-03-01 | $118.88M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $118.72M 10-Q · filed 2022-05-10 | $118.77M derived: sum of 2 quarters · filed 2023-03-01 | $118.77M derived: sum of 3 quarters · filed 2023-03-01 | $102.05M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $45.00K derived: sum of 2 quarters · filed 2023-03-01 | -$16.68M derived: sum of 3 quarters · filed 2023-03-01 | $85.80M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$16.72M derived: sum of 2 quarters · filed 2021-11-10 | $85.75M 10-Q · filed 2021-11-10 | $113.18M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | -$16.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $85.75M 10-Q · filed 2021-08-11 | $113.18M derived: sum of 3 quarters · filed 2021-08-11 | $113.20M derived: sum of 4 quarters · filed 2021-08-11 |
| 2020-03-31 | $102.47M 10-Q · filed 2021-05-11 | $129.90M derived: sum of 2 quarters · filed 2021-05-11 | $129.92M derived: sum of 3 quarters · filed 2021-05-11 | $129.93M derived: sum of 4 quarters · filed 2021-05-11 |
| 2019-12-31 | $27.43M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $27.45M derived: sum of 2 quarters · filed 2021-03-01 | $27.46M derived: sum of 3 quarters · filed 2021-03-01 | $27.52M 10-K · filed 2021-03-01 |
| 2019-09-30 | $18.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $29.00K derived: sum of 2 quarters · filed 2020-11-05 | $87.00K 10-Q · filed 2020-11-05 | $121.00K derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-30 | $11.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2020-08-06 | $69.00K 10-Q · filed 2020-08-06 | $103.00K derived: sum of 3 quarters · filed 2020-08-06 | $77.53M derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-31 | $58.00K 10-Q/A · filed 2020-05-26 | $92.00K derived: sum of 2 quarters · filed 2020-05-26 | $77.52M derived: sum of 3 quarters · filed 2020-05-26 | $111.53M derived: sum of 4 quarters · filed 2020-05-26 |
| 2018-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $77.46M derived: sum of 2 quarters · filed 2020-03-09 | $111.47M derived: sum of 3 quarters · filed 2020-03-09 | $111.59M 10-K · filed 2020-03-09 |
| 2018-09-30 | $77.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $111.44M derived: sum of 2 quarters · filed 2019-11-05 | $111.56M 10-Q · filed 2019-11-05 | $118.45M derived: sum of 4 quarters · filed 2019-11-05 |
| 2018-06-30 | $34.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $34.13M 10-Q · filed 2019-08-06 | $41.02M derived: sum of 3 quarters · filed 2019-08-06 | $41.02M derived: sum of 4 quarters · filed 2019-08-06 |
| 2018-03-31 | $119.00K 10-Q · filed 2019-05-07 | $7.01M derived: sum of 2 quarters · filed 2019-05-07 | $7.01M derived: sum of 3 quarters · filed 2019-05-07 | |
| 2017-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-06 | $6.89M derived: sum of 2 quarters · filed 2019-03-06 | $7.07M 10-K · filed 2019-03-06 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $177.00K 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | $177.00K 10-Q · filed 2018-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |